{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:05:56Z","timestamp":1789373156614,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.msard.2026.107428","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:18:13Z","timestamp":1785856693000},"page":"107428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A matter of formulation: Efficacy and tolerability of nabiximols and cannabis decoction for the treatment of multiple sclerosis-related spasticity"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-518X","authenticated-orcid":false,"given":"Arianna","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Colla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bratina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Benussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manganotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2026.107428_bib0001","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3109\/00207454.2013.812084","article-title":"Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study","volume":"123","author":"Arroyo","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.msard.2026.107428_bib0002","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fphar.2019.00701","article-title":"Development of standard operating protocols for the optimization of cannabis-based formulations for medical purposes","volume":"10","author":"Baratta","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2026.107428_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104863","article-title":"Cannabis-based products and multiple sclerosis-related pain: the role of routes of administration","volume":"77","author":"Barr\u00e9","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"17\u201318","key":"10.1016\/j.msard.2026.107428_bib0004","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1111\/jocn.16674","article-title":"Symptom severity is a major determinant of cannabis-based products use among people with multiple sclerosis","volume":"32","author":"Barr\u00e9","year":"2023","journal-title":"J. Clin. Nurs."},{"issue":"5","key":"10.1016\/j.msard.2026.107428_bib0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/medicina56050237","article-title":"Herbal preparations of medical cannabis: a vademecum for prescribing doctors","volume":"56","author":"Brunetti","year":"2020","journal-title":"Medicina"},{"issue":"6","key":"10.1016\/j.msard.2026.107428_bib0006","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00415-020-09739-x","article-title":"Predictors of Nabiximols (Sativex\u00ae) discontinuation over long-term follow-up: a real-life study","volume":"267","author":"Carotenuto","year":"2020","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107428_bib0007","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/jnnp-2019-322480","article-title":"Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2026.107428_bib0008","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1503\/cmaj.110837","article-title":"Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial","volume":"184","author":"Corey-Bloom","year":"2012","journal-title":"Can. Med. Assoc. J."},{"issue":"1","key":"10.1016\/j.msard.2026.107428_bib0009","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12883-021-02246-0","article-title":"Sativex\u00ae (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience","volume":"21","author":"Dhooghe","year":"2021","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107428_bib0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00415-018-8759-1","article-title":"Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy","volume":"265","author":"Dressler","year":"2018","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107428_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10072-015-2392-x","article-title":"Efficacy and safety of nabiximols (Sativex\u00ae) on multiple sclerosis spasticity in a real-life Italian monocentric study","volume":"37","author":"Ferr\u00e8","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107428_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD013444.pub2","article-title":"Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis","author":"Filippini","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.msard.2026.107428_bib0013","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.68.6.707","article-title":"Botulinum toxin (Dysport(R)) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study","volume":"68","author":"Hyman","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2026.107428_bib0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/practneurol-2018-002137","article-title":"Cannabis and multiple sclerosis","volume":"19","author":"Ingram","year":"2019","journal-title":"Pract. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.msard.2026.107428_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000357743","article-title":"Who benefits most from THC:CBD spray? Learning from clinical experience","volume":"71","author":"Koehler","year":"2014","journal-title":"Eur. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107428_bib0016","first-page":"12","article-title":"A regulatory take on cannabis and cannabinoids for medicinal use in the European Union","volume":"71","author":"Lipnik-\u0160tangelj","year":"2020","journal-title":"Arch. Ind. Hyg. Toxicol."},{"issue":"2","key":"10.1016\/j.msard.2026.107428_bib0017","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00207454.2018.1481066","article-title":"Sativex\u00ae as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial","volume":"129","author":"Markov\u00e0","year":"2019","journal-title":"Int. J. Neurosci."},{"issue":"2","key":"10.1016\/j.msard.2026.107428_bib0018","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1352458511419700","article-title":"A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex\u00ae (nabiximols)","volume":"18","author":"Notcutt","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2026.107428_bib0019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex\u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: sativex for refractory spasticity in MS","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107428_bib0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00207454.2012.762364","article-title":"Spasticity in multiple sclerosis: results of a patient survey","volume":"123","author":"Oreja-Guevara","year":"2013","journal-title":"Int. J. Neurosci."},{"issue":"11","key":"10.1016\/j.msard.2026.107428_bib0021","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/1352458516643600","article-title":"Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper","volume":"22","author":"Otero-Romero","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2026.107428_bib0022","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/ene.15412","article-title":"A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: analysis in relation to the newly described \u2018spasticity-plus syndrome","volume":"29","author":"Patti","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107428_bib0023","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/medicina56060309","article-title":"Oral administration of Cannabis and \u0394-9-tetrahydrocannabinol (THC) preparations: a systematic review","volume":"56","author":"Poyatos","year":"2020","journal-title":"Medicina"},{"issue":"7","key":"10.1016\/j.msard.2026.107428_bib0024","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14737175.2021.1935879","article-title":"Safety and tolerability of nabiximols oromucosal spray: a review of >15 years\u201d accumulated evidence from clinical trials","volume":"21","author":"Prieto Gonz\u00e1lez","year":"2021","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.msard.2026.107428_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugpo.2017.11.008","article-title":"Routes of administration for cannabis use \u2013 basic prevalence and related health outcomes: a scoping review and synthesis","volume":"52","author":"Russell","year":"2018","journal-title":"Int. J. Drug Policy."},{"key":"10.1016\/j.msard.2026.107428_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/656582","article-title":"Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation","volume":"2015","author":"Russo","year":"2015","journal-title":"Neural Plast."},{"key":"10.1016\/j.msard.2026.107428_bib0027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jns.2016.07.059","article-title":"The use of medical-grade cannabis in patients non-responders to Nabiximols","volume":"368","author":"Sacc\u00e0","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2026.107428_bib0028","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1007\/s10072-021-05182-6","article-title":"Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience","volume":"42","author":"Sartori","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107428_bib0029","series-title":"Riassunto Delle Caratteristiche del Prodotto","year":"2026"},{"issue":"1","key":"10.1016\/j.msard.2026.107428_bib0030","article-title":"Anti-spasticity agents for multiple sclerosis. Cochrane multiple sclerosis and rare diseases of the CNS group","volume":"2010","author":"Shakespeare","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.msard.2026.107428_bib0031","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-012-1441-0","article-title":"A phase I study to assess the single and multiple dose pharmacokinetics of THC\/CBD oromucosal spray","volume":"69","author":"Stott","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2026.107428_bib0032","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/JPR.S240011","article-title":"A review of scientific evidence for THC:CBD oromucosal spray (Nabiximols) in the management of chronic pain","volume":"Volume 13","author":"\u00dcberall","year":"2020","journal-title":"J. Pain. Res."},{"issue":"4","key":"10.1016\/j.msard.2026.107428_bib0033","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107428_bib0034","series-title":"Cannabis-related substances- Extracts and Tinctures of Cannabis \u2013 Section 4- Therapeutic use","article-title":"Expert Committee on Drug Dependence (ECDD)","year":"2018"},{"issue":"9395","key":"10.1016\/j.msard.2026.107428_bib0035","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:04:44Z","timestamp":1789369484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S2211034826004633"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107428","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A matter of formulation: Efficacy and tolerability of nabiximols and cannabis decoction for the treatment of multiple sclerosis-related spasticity","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107428"}}